BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35980655)

  • 1. Discordance Between Oncology Clinician-Perceived and Radiologist-Intended Meaning of the Postradiotherapy Positron Emission Tomography/Computed Tomography Freeform Report for Head and Neck Cancer.
    Patel Z; Schroeder JA; Bunch PM; Evans JK; Steber CR; Johnson AG; Farris JC; Hughes RT
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):927-934. PubMed ID: 35980655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Intensive 18F-Fludeoxyglucose-Positron Emission Tomography With Computed Tomography-Based Strategy of Follow-Up in Patients Treated for Head and Neck Squamous Cell Carcinoma Who Are Clinically Asymptomatic.
    Leclère JC; Clément C; Le Pennec R; Maheo C; Gujral DM; Schick U; Le Gal G; Marianowski R; Salaun PY; Abgral R
    JAMA Netw Open; 2023 Aug; 6(8):e2326654. PubMed ID: 37526935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinoma.
    Hsu D; Rath TJ; Branstetter BF; Anzai Y; Phillips CD; Juliano AF; Mosier KM; Bazylewicz MP; Poliashenko SM; Kulzer MH; Rhyner PA; Risk B; Wiggins RH; Aiken AH
    Radiol Imaging Cancer; 2021 May; 3(3):e200131. PubMed ID: 34018845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
    Dejaco D; Uprimny C; Widmann G; Riedl D; Moser P; Arnold C; Steinbichler TB; Kofler B; Schartinger VH; Virgolini I; Riechelmann H
    Cancer Imaging; 2020 Sep; 20(1):69. PubMed ID: 32993805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS.
    Paul S; Gupta T; Purandare N; Joshi K; Ghosh-Laskar S; Budrukkar A; Swain M; Sinha S; Kumar A; Joshi A; Prabhash K; Nair S; Rangarajan V; Agarwal JP
    Otolaryngol Head Neck Surg; 2023 Oct; 169(4):938-947. PubMed ID: 36856038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
    Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Pretreatment and 3-Month
    Mayo Z; Seyedin SN; Mallak N; Mott SL; Menda Y; Graham M; Anderson C
    Ann Otol Rhinol Laryngol; 2019 Jul; 128(7):595-600. PubMed ID: 30808209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG PET-CT for response evaluation in head and neck malignancy: Experience from a tertiary level hospital in south India.
    Benjamin J; Hephzibah J; Shanthly N; Oommen R; Mathew D; Pavamani S; Rajnikanth J
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1333. PubMed ID: 33660434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Ferrari C; Santo G; Mammucci P; Rubini D; Sciacqua A; Sardaro A; Pisani AR; Rubini G
    BMC Med Imaging; 2023 Feb; 23(1):34. PubMed ID: 36814217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT Versus Standard Imaging for Prediction of Survival in Patients with Recurrent Head and Neck Squamous Cell Carcinoma.
    Rohde M; Nielsen AL; Pareek M; Johansen J; Sørensen JA; Diaz A; Nielsen MK; Christiansen JM; Asmussen JT; Nguyen N; Gerke O; Thomassen A; Alavi A; Høilund-Carlsen PF; Godballe C
    J Nucl Med; 2019 May; 60(5):592-599. PubMed ID: 30315144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomechanical imaging biomarker during chemoradiotherapy predicts treatment response in head and neck squamous cell carcinoma.
    Fujimoto K; Shiinoki T; Kawazoe Y; Yuasa Y; Mukaidani W; Manabe Y; Kajima M; Tanaka H
    Phys Med Biol; 2024 Feb; 69(5):. PubMed ID: 38359451
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.
    Yao M; Smith RB; Hoffman HT; Funk GF; Lu M; Menda Y; Graham MM; Buatti JM
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):9-14. PubMed ID: 18930358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 19. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.
    Marcus C; Ciarallo A; Tahari AK; Mena E; Koch W; Wahl RL; Kiess AP; Kang H; Subramaniam RM
    J Nucl Med; 2014 Sep; 55(9):1411-6. PubMed ID: 24947059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.